Mode
Text Size
Log in / Sign up
Phase 3 N=66 Randomized Triple-blind Treatment

Laser Acupuncture for Postpartum Weight Retention

Postpartum Weight Retention

Enrolled (actual)
66
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcome: Primary: Body Mass Index (BMI) — 33.62; 28.03; 26.90; 26.99 kg/m^2

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
laser acupuncture (Procedure); sham laser acupuncture (Procedure)
Age
Adult · 20+ yrs
Sex
Female
Sponsor
Chang Gung Memorial Hospital
Primary completion
Dec 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Body Mass Index (BMI)
33.62; 28.03; 26.90; 26.99; 26.16; 26.64
SECONDARY
Waist-to-buttock Ratio (WBR)
0.93; 0.92; 0.92; 0.90
SECONDARY
Body Fat Percentage (BFP)
36.94; 36.02; 35.75; 35.37

Summary

Objective: To determine the therapeutic effect of acupuncture on postpartum weight retention. Methods: 66 subjects after delivery with postpartum weight retention will be randomly divided into laser acupuncture and control group. A single-blind clinical trial will be conducted and the subjects will be treated with verum or sham laser acupuncture 5 sessions per week. After about 3 weeks of treatment, the differences of the subjects' body weight, body mass index, and waist circumference will be analyzed with ANOVA between laser acupuncture and control group.

Eligibility Criteria

Inclusion Criteria

  • postpartum duration of 25;
  • age > 20 years;
  • did not use any other medications for weight loss during the study period; and
  • provided informed consent.

Exclusion Criteria

  • presence of a pacemaker;
  • history of seizure or epilepsy;
  • taking immunosuppressant medication;
  • cancer;
  • infectious disease of the skin;
  • taking medications for weight loss, including Chinese herbal preparations, during the study period;
  • receiving other treatment, including supplements, herbs, and medications for weight gain prior to entering the study;
  • comorbidities (hypothyroidism, renal disease, etc.) that the physician believes would affect the findings;
  • unable to undergo LAT due to other medical conditions; and
  • lack of informed consent.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02840916). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search